MedTrace Logo

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

NCT01362426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2016-03-10

No results posted yet for this study

Summary

The primary objective of this study is to determine if Australian patients with schizophrenia treated with paliperidone palmitate under conditions of continuous monitoring of outcomes over a 12-month period achieve relapse rates comparable to published literature.

Conditions

Interventions

DRUG

paliperidone palmitate

Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.

Sponsors & Collaborators

  • Janssen-Cilag Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Pty Ltd Clinical Trial · Janssen-Cilag Pty Ltd

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01362426 on ClinicalTrials.gov